News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Mark M. Awad/mskcc.org
Jan 15, 2025, 15:32

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Dipesh Uprety, Assistant Professor of Thoracic Oncology at the Barbara Ann Karmanos Cancer Institute, shared an article by Mark M. Awad on X:

“Phase III CheckMate-816 Journal of Clinical Oncology Neoadjuvant Nivo + Ipi vs Chemo:-

  • Md EFS 54.8 mo vs 20.4 mo.
  • pCR 20.4 vs 4.6 MPR 28.3 vs 14.8%.
  • pCR or MPR had higher baseline 4-gene inflammatory scores than those without in IO arm.”

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.

Authors: Mark M. Awad, et al.

 

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Dipesh Uprety, Assistant Professor of Thoracic Oncology at the Barbara Ann Karmanos Cancer Institute, specializes in treating lung cancer, mesothelioma, thymoma, and thymic carcinoma. He also serves as the Editor-in-Chief of The Cancer News, an authoritative resource on cancer-related topics.

Barbara Ann Karmanos Cancer Institute cancer chemotherapy clinical oncology Dipesh Uprety fight against cancer Global fight against cancer ipilimumab Lung cancer Mark M. Awad neoadjuvant nivolumab OncoDaily Oncology
Special Coverage
Blog
Apr 14, 2025, 03:45
Alfredo Addeo: The Phase 3 DeLLphi-304 trial met its primary endpoint
Blog
Apr 14, 2025, 01:50
Giannis Mountzios: Tarlatamab Improves Overall Survival in Advanced SCLC
Blog
Apr 14, 2025, 01:36
Sumanta K. Pal: Best Talk This Year - City of Hope GU Retreat
Blog
Apr 14, 2025, 01:08
The Faces of Cancer Care: Strengthening the Workforce, Saving Lives - UICC
Blog
Apr 13, 2025, 19:03
Tigran Byuzandyan: Delegation from the National Oncology Center of Armenia Explores Collaboration with Heidelberg University Hospital
Blog
Apr 13, 2025, 18:24
Akhil Santhosh: First-Line Adagrasib and Pembrolizumab for Metastatic NSCLC
Blog
Apr 13, 2025, 18:15
12th Annual Cholangiocarcinoma Foundation Conference Comes to a Close
Blog
Apr 13, 2025, 17:50
Noemi Reguart: First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy in SCLC
Blog
Apr 13, 2025, 17:15
Applications are open for the M2ICOS project - European School of Oncology
Stories
Apr 13, 2025, 17:11
From Resident to Survivor: Dr. Jessica Firdman Moore’s cancer journey at Sylvester Comprehensive Cancer Center
Blog
Apr 13, 2025, 17:05
Aruni Ghose: OncoFlow to evaluate AI models across the cancer continuum for clinical adoption
Blog
Apr 13, 2025, 16:53
Heitham Hassoun: All great hospitals are so much more than places to heal